Patrik Jeanmonod - 08 Sep 2022 Form 4 Insider Report for Cytek Biosciences, Inc. (CTKB)

Role
Chief Financial Officer
Signature
/s/ Valerie Barnett, Attorney-in-Fact for Patrik Jeanmonod
Issuer symbol
CTKB
Transactions as of
08 Sep 2022
Net transactions value
+$16,000
Form type
4
Filing time
23 Feb 2023, 17:34:53 UTC
Previous filing
25 Aug 2022
Next filing
28 Sep 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTKB Common Stock Options Exercise $16,000 +40,000 +53% $0.4000* 116,132 08 Sep 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTKB Employee Stock Option (Right to Buy) Options Exercise $0 -40,000 -16% $0.000000 202,661 08 Sep 2022 Common Stock 40,000 $0.4000 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Forms 4 filed after the date of the option exercise reported in this Form 4 incorrectly underreported total ownership by 40,000 shares. The number of securities beneficially owned following this option exercise is reflected as of February 17, 2022.
F2 The shares subject to the option vest as follows: 25% of the shares subject to the option vests on October 15, 2019; and 1/48th of the shares subject to the option vest monthly thereafter over the following three years.